FDA AdCom recommends no CV trial for PAMORA class US FDA

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jun 13, 2014 at 2:15 AM

FDA AdCom recommends no CV trial for PAMORA class

US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK AstraZeneca announced today that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes MOVANTIKTM (naloxegol oxalate), an investigational treatment for opioid -induced constipation (OIC) for patients with chronic non-cancer pain. Following a clarification of the vote, the majority of the Committee suggested continued post-approval data collection for cardiovascular safety. The FDA convened a meeting of the AADPAC to review the class of peripherally acting opioid receptor antagonists on 11-12 June 2014. The meeting assessed the necessity, timing, design and size of cardiovascular outcomes trials to support approval of products in the class, for the proposed indication of OIC in patients taking opioids for chronic non-cancer pain. The FDA is not bound by the Advisory Committee's recommendation, but takes its advice into consideration when reviewing applications for investigational medicines. The Prescription Drug User Fee Act (PDUFA) date set by the FDA for MOVANTIK is 16 September 2014. Briggs Morrison, Executive Vice President, Global Medicines Development and Chief Medical Officer said: "We are pleased that the Committee did not find it necessary to require a cardiovascular outcomes trial for the PAMORA class. We look forward to the outcome of the FDA's review of the New Drug Application for MOVANTIK and the potential to provide patients with chronic non-cancer pain affected by OIC with an additional treatment option." Opioids play an important role in chronic pain relief by binding mu-receptors in the brain, but they also bind mu-receptors in the bowel. That is why patients taking opioids for chronic pain can develop OIC. In fact, the incidence of OIC can be as high as 81% in patients taking opioids. There is a significant unmet need for safe, effective treatment options for patients with OIC. An estimated 235 million prescriptions for opioids are written in the US each year, of which 20% are for chronic pain. For patients taking prescription opioids for chronic pain, constipation is one of the most common side effects and one not adequately relieved by laxatives. If approved, MOVANTIK has the potential to be the first once-daily, oral PAMORA for the treatment of OIC for patients with chronic non-cancer pain. MOVANTIK is also under regulatory review with health agencies in the European Union and Canada. On 4 June 2014 the New England Journal of Medicine published data online from two pivotal Phase III studies of MOVANTIK, KODIAC-4 and KODIAC-5. Both studies met their primary endpoint, showing an improvement in treatment effect versus placebo: more OIC non-cancer pain patients treated with MOVANTIK at a 25 mg dose had a consistent response of increased spontaneous bowel movements through 12 weeks of treatment compared to placebo. About MOVANTIKTM (naloxegol oxalate) MOVANTIK is an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA) specifically designed for the treatment of opioid-induced constipation (OIC) in patients with chronic non-cancer pain. In the Phase III clinical studies, MOVANTIK was administered as a once-daily tablet and is designed to block the binding of opioids to the opioid receptors in the gastrointestinal (GI) tract without impacting the opioid receptors in the brain. MOVANTIK is part of the exclusive worldwide licence agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics. MOVANTIK was developed using Nektar's oral small molecule polymer conjugate technology. About Opioid-Induced Constipation (OIC) Opioids play an important role in chronic pain relief by binding mu-receptors in the brain. But they also bind mu-receptors in the bowel. That is why patients taking opioids for chronic pain can develop opioid-induced constipation (OIC). In fact, the incidence of OIC varies and has been reported as high as 81% in patients taking opioids. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Esra Erkal-Paler +44 20 7604 8030 (UK/Global) Vanessa Rhodes +44 20 7604 8037 (UK/Global) Ayesha Bharmal +44 20 7604 8034 (UK/Global) Michele Meixell +1 302 885 2677 (US) Jacob Lund +46 8 553 260 20 (Sweden) Investor Enquiries Karl Hård +44 20 7604 8123 mob: +44 7789 654364 Colleen Proctor +44 207 604 8128 mob: +1 302 357 4882 Anthony Brown +44 20 7604 8067 mob: +44 7585 404943 Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729 13 June 2014 -ENDS-

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bugsy Siegel's Cold Case: Museum Exhibit Revisits Unsolved Murder

Whoever thought sleuthing around organized crime’s dark corridors would land you inside Las Vegas' Mob Museum, tracing the cold case trail of none other than Bugsy Siegel? Yeah, the notorious mobster whose murder on June 20, 1947, has remained frozen in mystery like a stiff in cement shoes. Now, as we inch closer to the 80-year mark since Siegel was shot dead in Beverly...

Tech's Role in Shaping Tomorrow's Classroom: 2026 Insights

Schools at a Crossroads: Career Skills Take Center Stage The data's out, and boy, is it telling. Project Tomorrow's 23rd Annual Speak Up Report brings a bushel of insights—some you'd expect, some that'll knock your socks off. With over 95,000 K-12 folks raising their voices, this is no small potatoes look into modern education's heartbeat. Parents Crying Out for...

Celebrate Dr. David Neff's Healthcare Legacy

An Icon in Medicine and Innovation Dr. David R. Neff's recognition as a Pinnacle Lifetime Member marks a storied journey through medicine and healthcare innovation. Decades of Dedication to Patient Care For over 45 years, Neff carved out a niche in medicine that few can parallel. His overarching focus on infectious disease, cancer, and more represents a holistic approach...

Centrus Ships Centrifuges to Boost U.S. Uranium Capacity

A Surge in Centrifuge Production This ain't exactly the kind of news you read over a breakfast special, but it's a biggie if you're watching the energy sector. Centrus Energy (NYSE: LEU) has just fired up the engines on their uranium enrichment expansion, shipping the first lot of their brand-spankin'-new centrifuges from Tennessee to Ohio. From here, they're looking to...

Jay Group Expands to Houston with New Fulfillment Hub

Jay Group's Bold Move in the Logistics Arena In a no-holds-barred expansion, Jay Group's got themselves a brand new sprawling 250,000-square-foot fulfillment hub deep in the heart of Houston. Now, folks, this isn’t just another warehouse. We're talking a 3PL powerhouse that allows coast-to-coast delivery, hitting 90% of U.S. consumers in just a couple of days. If you're...

Quanta Services Reports Record Q3 2026 Earnings

Quanta Services Smashes Q3 2026 Expectations If you're a stakeholder in Quanta Services, you'd probably be dancing in the aisles right now. This company just posted off-the-charts numbers for the third quarter of 2026. We're talking revenues of $12 billion—a staggering leap from $7.63 billion the same quarter last year. Explosive Earnings and Strong Backlog The star of...

Quad Sees Marginal Gains Amid Industry Challenges

Treading Water with a Splash of Strategic Moves When you're in the thick of market shifts, sometimes it's not about big leaps but staying afloat with purpose. That's what Quad's recent financial release seems to hint at. A steady net sales figure hovering at $587 million for Q3 2026, barely a nudge compared to last year's numbers, sets the tone. It's not the fireworks...

Thunderly Bags Davey Awards for Creative Franchise Videos

Big Wins from Humble Beginnings Ever notice how some small outfits have a knack for punching above their weight? Thunderly, a Dallas-based marketing agency, is a shining example of that. They've just snagged two Silver Awards at the 22nd Annual Davey Awards—and it’s stirring up talk across the sector. Winning a Davey isn’t child's play; it’s about small teams...

Cohere's CAD $7 Billion Raise Signals AI Power Shift

Changing the Game: Cohere's Massive Series E Raise There's a seismic shift happening up north, and it’s not the aurora borealis. Cohere just announced the initial close of a staggering CAD $7 billion Series E funding round, eyeing a CAD $35.7 billion valuation. If it pans out, it’d be the kind of cash grab that's never been seen in Canadian tech history. Why This...

xTool X1: Redefining Laser Fabrication for Makers

The Next Generation of Laser Fabrication Whenever a new gizmo hits the market, it's usually just an upgrade in disguise—faster, shinier, a touch more wattage. Not this time. xTool shook things up by rolling out the X1, a laser platform that gets what small businesses and makers truly crave: versatility and long-lasting potential. This bad boy does more than engrave; it...